BioPlan Associates

Oct 21, 2024 | outsourcedpharma.com | Louis Garguilo |BioPlan Associates |Ioanna Deni |Anjeanette Ormonde

It’s not magic -- it’s science. With KBI Biopharma’s SUREmAb™ solution, your mAb development moves faster and smarter. Get minimum titers of 4 g/L and up to 10g/L for your IgG monoclonal antibodies before process optimization and tox material in just 6.5 months from transfection—guaranteed. Built on the SUREtechnology Platform™, powered by Selexis®, that has enabled bringing over 110 mAbs to clinic and 7 to market. Set your mAb program on the fast track.

Oct 11, 2024 | bioprocessonline.com | Ioanna Deni |BioPlan Associates

By Ioanna Deni, BioPlan Associates, Inc. For over 10 years, downstream bioprocessing (DSP) capacity has been considered an Achilles' heel of biomanufacturing, with purification and separation steps notoriously slowing production. According to the 21st Annual Survey of Biopharmaceutical Manufacturing Capacity and Production, these challenges began as upstream titers coming from bioreactors were increasing and productivity was improving. Downstream innovations were slower to keep up.

Nov 14, 2023 | bioprocessonline.com | Erica Friedman |BioPlan Associates

Guest Column | November 14, 2023 By Erica Friedman, senior research analyst, BioPlan Associates Over the past 20 years that our Annual Biopharmaceutical Manufacturing Report1 has measured adoption of single-use systems (SUS) and modular technologies in bioprocessing, they have clearly become critical to bioprocessing. The trend continues to be driven by demand for efficiency and flexibility and the need for more innovative manufacturing.

Oct 4, 2023 | outsourcedpharma.com | Erica Friedman |BioPlan Associates |Louis Garguilo

Get more pharma outsourcing insight with our FREE newsletter Guest Column | October 4, 2023 By Erica Friedman, senior research analyst, BioPlan Associates Only a minority of biologics are manufactured entirely in-house, and that percentage continues to decline.

Oct 4, 2023 | lifescienceleader.com | Erica Friedman |BioPlan Associates

Sign up today for your FREE subscription to Life Science Leader Magazine! Guest Column | October 4, 2023 By Erica Friedman, senior research analyst, BioPlan Associates Only a minority of biologics are manufactured entirely in-house, and that percentage continues to decline.